Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Despite widespread use of Pegylated forms of Inteferon in the management of Myeloproliferative Neoplasms (MPN), most clinicians have experience predominantly with peginterferon alfa-2a (Pegasys). Third generation pegylated IFNα, ropeginterferon alfa-2b (ropegIFN; Besremi), was recommended by the European Medicine Authority (EMA) for treatment of Polycythaemia Vera (PV) following a Phase III trial (PROUD-PV / CONTINUATION-PV). FDA approval for PV, regardless of treatment history, was subsequently granted in November 2021. We hereby demonstrate the safety and tolerability of ropegIFN in a series of MPN patients at variable doses. It corroborates reports of efficacy of ropegIFN in patients with PV and use in pregnancy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9801096 | PMC |
| http://dx.doi.org/10.1016/j.lrr.2022.100360 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Accidental Fall Revealing an Atypical Presentation of a Rare Disease: A Case of Budd-Chiari Syndrome.
Cureus
July 2025
Internal Medicine, King's College Hospital London, Dubai, ARE.
Budd-Chiari syndrome (BCS) is a rare vascular disorder characterized by hepatic venous outflow obstruction. Polycythemia vera (PV) is a common underlying etiology contributing to BCS. The diagnosis of metabolic dysfunction-associated steatohepatitis (MASH) in this case warrants reconsideration based on recent diagnostic criteria.
View Article and Find Full Text PDFErythromelalgia: a cutaneous manifestation of polycythemia vera.
J Osteopath Med
September 2025
Forefront Dermatology, Noblesville, IN, USA.
Progression of carotid plaque burden in patients with polycythemia vera and essential thrombocythemia.
Blood Res
September 2025
Division of Hematology & Medical Oncology, Department of Internal Medicine, Soonchunhyang University Seoul Hospital, 59 Daesagwan-Ro, Yongsan-Gu, Seoul, 04401, Republic of Korea.
Purpose: Prevention of vascular events is the main objective in patients with polycythemia vera (PV) or essential thrombocythemia (ET). Carotid ultrasonography (USG) is a safe and noninvasive diagnostic tool that can be used to stratify cardiovascular and stroke risks. In our previous study, carotid plaque burden was significantly higher in patients with PV/ET than in the general population.
View Article and Find Full Text PDFOld Therapy, New Questions: Rethinking Phlebotomy in a Pharmacologic Landscape.
Pharmaceuticals (Basel)
August 2025
Hematology and Bone Marrow Transplantation Unit (BMTU), Hospital of Bolzano (SABES-ASDAA), Teaching Hospital of Paracelsus Medical University (PMU), 39100 Bolzano, Italy.
Therapeutic phlebotomy remains a key intervention in the management of erythrocytosis and iron overload disorders, particularly polycythemia vera (PV) and hereditary hemochromatosis. Despite its historical origins as an ancient practice, venesection continues to be recommended in international guidelines for the reduction of hematocrit and iron burden, thereby mitigating thrombotic and organ-related complications. However, the evolving landscape of targeted pharmacologic therapies is reshaping the therapeutic paradigm.
View Article and Find Full Text PDFErythroid activity modulates iron regulation in pathological erythropoiesis: A cross-sectional case-control study.
Indian J Med Res
June 2025
Department of Haematology, Christian Medical College, Vellore, Tamil Nadu, India.
Background & objectives Genetic defects and altered synthesis of RBCs characterise β-thalassemia and polycythaemia vera (PV), respectively. In both diseases, stress erythropoiesis leads to accelerated erythroid expansion, although iron regulation has not been well studied. Here, we analysed iron parameters and iron regulatory gene expression in individuals affected with β-thalassemia and PV.
View Article and Find Full Text PDF